Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

References for PMC Articles for PubMed (Select 18474729)

1.

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M.

Neurology. 2007 May 22;68(21):1800-8. Epub 2007 Apr 25.

PMID:
17460158
3.

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group.

Neuropsychopharmacology. 2005 Jun;30(6):1204-15.

4.

Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review.

Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN.

Neuroepidemiology. 2004 Jul-Aug;23(4):159-69. Review.

PMID:
15279021
5.

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group.

Neurology. 2004 Jan 13;62(1):66-71.

PMID:
14718699
6.

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study.

JAMA. 2003 Jun 4;289(21):2819-26.

PMID:
12783912
7.

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study.

Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC; Cache County Study Investigators.

Neurology. 2002 Sep 24;59(6):880-6.

PMID:
12297571
8.

Inflammation in neurodegenerative disease--a double-edged sword.

Wyss-Coray T, Mucke L.

Neuron. 2002 Aug 1;35(3):419-32. Review.

PMID:
12165466
9.

Randomized pilot study of nimesulide treatment in Alzheimer's disease.

Aisen PS, Schmeidler J, Pasinetti GM.

Neurology. 2002 Apr 9;58(7):1050-4.

PMID:
11940691
10.

Double placebo design in a prevention trial for Alzheimer's disease.

Martin BK, Meinert CL, Breitner JC; ADAPT Research Group.

Control Clin Trials. 2002 Feb;23(1):93-9.

PMID:
11852171
11.

Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.

in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH.

N Engl J Med. 2001 Nov 22;345(21):1515-21.

12.

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH.

Nature. 2001 Nov 8;414(6860):212-6.

PMID:
11700559
13.

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N.

Neurology. 1999 Jul 13;53(1):197-201.

PMID:
10408559
14.
16.

Protective effect of chronic NSAID use on cognitive decline in older persons.

Rozzini R, Ferrucci L, Losonczy K, Havlik RJ, Guralnik JM.

J Am Geriatr Soc. 1996 Sep;44(9):1025-9.

PMID:
8790225
17.

Sample size calculation for complex clinical trials with survival endpoints.

Shih JH.

Control Clin Trials. 1995 Dec;16(6):395-407.

PMID:
8720017
18.

Clinical trial of indomethacin in Alzheimer's disease.

Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al.

Neurology. 1993 Aug;43(8):1609-11.

PMID:
8351023
19.

Cognitive dysfunction associated with naproxen and ibuprofen in the elderly.

Goodwin JS, Regan M.

Arthritis Rheum. 1982 Aug;25(8):1013-5. No abstract available.

PMID:
7115443
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk